Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results

U.S. producer prices rose 1.3% month over month in September, more than double the 0.5% expected, while retail sales increased 0.8% versus a 0.3% estimate. U.S. stocks were mixed: the Dow gained 0.93%, the S&P 500 rose 0.16%, and the Nasdaq fell 0.24%; oil climbed 2.8% to $97.77. Schwab shares fell about 3% after mixed Q3 results, while FMC dropped 35% after cutting revenue guidance and forecasting $625 million to $675 million in charges.

Analysis

The macro mix is more consequential than the index split: firm consumption and labor data alongside a sharp producer-price surprise raise the risk that yields reprice higher before growth rolls over. Near term, that challenges rate-sensitive financials and long-duration equities; over 1–3 months, the key test is whether inflation feeds through to margins and policy expectations or proves concentrated in producer inputs. Strong demand is not an unambiguous positive if input costs outrun pricing power.

At OPKO Health, the asset sale may improve liquidity, but the headline consideration is not equivalent to value retained by OPKO: verify exactly which assets and liabilities transfer, stranded costs, earnout conditions, and use of proceeds. Labcorp may gain scale or capabilities, but integration and execution—not the announced price alone—determine returns. FMC’s severe repricing signals credibility and earnings-reset risk; charges may be partly noncash, but the guide cut makes cash generation, debt capacity, and subsequent outlook the decisive checks. Avoid assuming a low share price is a floor. ManpowerGroup’s miss is a read-through to employer demand, but one quarter does not establish a durable labor downturn.

SCHW’s EPS beat is less informative than revenue delivery and the sensitivity of deposit/funding economics to rates. PAG’s take-private premium is event-driven, with financing, shareholder approval, and closing terms governing the remaining spread. The main contrarian risk is treating a single hot PPI print as proof of persistent inflation—or dismissing it because equities held up; follow-through in yields and subsequent inflation data matter more than this session’s breadth.

Key Decisions for Investors

• Macro: avoid adding broad duration exposure immediately; use subsequent PPI/CPI releases and Treasury yields as confirmation. A reversal in yields after cooler inflation would falsify the near-term rate-pressure thesis.
• OPK/Labcorp: treat the transaction as a catalyst, not a clean earnings upgrade. Watch the asset perimeter, net proceeds after obligations, earnout terms, and OPKO’s next liquidity disclosure before sizing a follow-through position; failure to realize cash or material stranded costs would undermine the positive read.
• FMC: do not chase the post-drop move either way. Require updated cash-flow and leverage outlook, charge composition, and evidence the revenue guide has stabilized; another cut or weaker liquidity metrics would support further downside, while a credible forecast reset and stable cash generation would weaken it.
• Event-driven: for PAG, monitor definitive deal terms and financing/approval milestones rather than extrapolating the initial jump; a widening deal spread or delayed close is the risk signal. For SCHW and MAN, wait for funding-cost/deposit trends and employer-demand evidence, respectively, before treating one quarter as a durable earnings trend.